Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

How Will the “Opioid Crisis” Impact the Care of Oncology and Palliative Care Patients


Description:
The purpose of this activity is to educate participants on required changes in practice related to pain management in oncology and palliative care patients. Recommendations on how to assess patient risk in the oncology and palliative care population given the lack of validated tools in these patient populations. Discuss why oncology and palliative care patients are not exempt from risk and may require opioid pain management despite history of opioid misuse.

Objectives:

  1. Review developments and trends in opioid prescribing that have led to greater scrutiny of the routine use of opioids for pain management.
  2. Outline legislative actions taken to curtail the “opioid crisis” in Massachusetts and other New England States.
  3. Explore the impact upon patients, prescribers, and pharmacists given the legislative developments, with focus upon oncology and palliative care settings.
  4. Recommend tools for pharmacists and other health care professionals for identifying oncology and palliative care patients at risk of opioid misuse and patient management strategies.
Activity Number:
0280-0000-16-085
-H01-P

This recorded activity is a based on a live program that was offered on October 15, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
Bridget Scullion, PharmD, BCOP; Clinical Pharmacy Manager, Dana-Farber Cancer Institute
Dr. Scullion is on the advisory board of Insys  
 
The reviewer is Zaven Norigian, PharmD, BCOP; Pharmacy Clinical Specialist, Oncology, Lahey Clinic
Department of Pharmacy, Burlington, Massachusetts
Dr. Norigian is on the speaker’s bureau of Merck and is also on the advisory boards of Amgen, BMS, Eisai, Lilly, Pfizer and Taiho
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The purpose of this activity is to educate participants on required changes in practice related to pain management in oncology and palliative care patients. Recommendations on how to assess patient risk in the oncology and palliative care population given the lack of validated tools in these patient populations. Discuss why oncology and palliative care patients are not exempt from risk and may require opioid pain management despite history of opioid misuse.
 

Objectives

  • Review developments and trends in opioid prescribing that have led to greater scrutiny of the routine use of opioids for pain management.
  • Outline legislative actions taken to curtail the “opioid crisis” in Massachusetts and other New England States.
  • Explore the impact upon patients, prescribers, and pharmacists given the legislative developments, with focus upon oncology and palliative care settings.
  • Recommend tools for pharmacists and other health care professionals for identifying oncology and palliative care patients at risk of opioid misuse and patient management strategies.

Speaker(s)/Author(s)

Bridget Scullion,  picture

Bridget Scullion, , PharmD, BCOP
Director of Clinical Pharmacy Services, Dana Farber Cancer Institute


Brief Bio : Director of Clinical Pharmacy Services, Dana-Farber Cancer Institute

Activity Number

0280-0000-16-085-H01-P

Release Date: Nov 22, 2016
Credit Expiration Date: Nov 22, 2018

CE Hours

1.00

Fee

$0.00
 

The CE Activity developed by American Health Resources Inc